Loading...
•
Sep 30, 2024
Carisma Therapeutics Q3 2024 Earnings Report
Carisma Therapeutics reported financial results for the third quarter of 2024 and highlighted recent business updates.
Key Takeaways
Carisma Therapeutics reported its Q3 2024 financial results, with a focus on advancing its clinical and preclinical programs, including the anticipated initial data from the Phase 1 study of CT-0525 in Q1 2025 and the nomination of a development candidate for the liver fibrosis program also expected in Q1 2025. The company's cash and cash equivalents are expected to fund operations into the third quarter of 2025.
Initial results from the Phase 1 study of CT-0525 are expected in the first quarter of 2025.
A development candidate for the liver fibrosis program is expected to be nominated in the first quarter of 2025.
New preclinical efficacy data from the anti-GPC3 in vivo CAR-M therapy will be presented at the SITC 2024 Annual Meeting on November 8.
New preclinical efficacy data in liver fibrosis will be presented at AASLD - The Liver Meeting ® 2024 on November 17.
Forward Guidance
Carisma Therapeutics anticipates that its cash and cash equivalents of $26.9 million as of September 30, 2024, are sufficient to sustain its planned operations into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...